| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INGN Stock Overview
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally.
Rewards
Risk Analysis
No risks detected for INGN from our risk checks.
Inogen Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.16 |
| 52 Week High | US$82.35 |
| 52 Week Low | US$22.51 |
| Beta | 1 |
| 1 Month Change | 4.39% |
| 3 Month Change | -17.94% |
| 1 Year Change | -60.66% |
| 3 Year Change | -60.82% |
| 5 Year Change | -72.58% |
| Change since IPO | 72.67% |
Recent News & Updates
Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds
Inogen lacks the economic pillars to outplay macro-economic and industry-specific headwinds plaguing its share price. Supply shortages have destructed output and clamped down on margins, whilst COGS continues to spike. The company has expanded its rep count, reducing the target revenue per rep requirement to meet FY22 guidance.
Shareholder Returns
| INGN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.9% | 7.0% | 6.6% |
| 1Y | -60.7% | -23.7% | -18.5% |
Return vs Industry: INGN underperformed the US Medical Equipment industry which returned -25.1% over the past year.
Return vs Market: INGN underperformed the US Market which returned -20.5% over the past year.
Price Volatility
| INGN volatility | |
|---|---|
| INGN Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 10.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: INGN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,021 | Nabil Shabshab | https://www.inogen.com |
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories.
Inogen Fundamentals Summary
| INGN fundamental statistics | |
|---|---|
| Market Cap | US$603.55m |
| Earnings (TTM) | -US$19.81m |
| Revenue (TTM) | US$351.46m |
1.7x
P/S Ratio-30.1x
P/E RatioIs INGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INGN income statement (TTM) | |
|---|---|
| Revenue | US$351.46m |
| Cost of Revenue | US$179.84m |
| Gross Profit | US$171.62m |
| Other Expenses | US$191.43m |
| Earnings | -US$19.81m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 48.83% |
| Net Profit Margin | -5.64% |
| Debt/Equity Ratio | 0% |
How did INGN perform over the long term?
See historical performance and comparisonValuation
Is INGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INGN?
Other financial metrics that can be useful for relative valuation.
| What is INGN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$603.55m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 45.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does INGN's PS Ratio compare to its peers?
| INGN PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 52.8x |
Price-To-Sales vs Peers: INGN is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (52.8x).
Price to Earnings Ratio vs Industry
How does INGN's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Sales vs Industry: INGN is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Medical Equipment industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is INGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.7x |
| Fair PS Ratio | 2.1x |
Price-To-Sales vs Fair Ratio: INGN is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).
Share Price vs Fair Value
What is the Fair Price of INGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INGN ($26.16) is trading below our estimate of fair value ($38.43)
Significantly Below Fair Value: INGN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INGN's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Inogen forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
54.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INGN's revenue (9% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: INGN's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INGN is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Inogen performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-41.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INGN is currently unprofitable.
Growing Profit Margin: INGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INGN is unprofitable, and losses have increased over the past 5 years at a rate of 41.8% per year.
Accelerating Growth: Unable to compare INGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: INGN has a negative Return on Equity (-5.53%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Inogen's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: INGN's short term assets ($318.1M) exceed its short term liabilities ($59.8M).
Long Term Liabilities: INGN's short term assets ($318.1M) exceed its long term liabilities ($56.5M).
Debt to Equity History and Analysis
Debt Level: INGN is debt free.
Reducing Debt: INGN had no debt 5 years ago.
Debt Coverage: INGN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INGN has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is Inogen current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INGN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INGN has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
0.9yrs
Average management tenure
CEO
Nabil Shabshab (56 yo)
1.33yrs
Tenure
US$7,036,373
Compensation
Mr. Nabil Shabshab is President, Chief Executive Officer and Director at Inogen, Inc. since joining on February 8, 2021. He served as Worldwide President of Diabetes Care and Digital Health at Becton, Dick...
CEO Compensation Analysis
Compensation vs Market: Nabil's total compensation ($USD7.04M) is above average for companies of similar size in the US market ($USD4.08M).
Compensation vs Earnings: Insufficient data to compare Nabil's compensation with company performance.
Leadership Team
Experienced Management: INGN's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
Experienced Board: INGN's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Inogen, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Inogen, Inc.
- Ticker: INGN
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$603.550m
- Shares outstanding: 22.84m
- Website: https://www.inogen.com
Number of Employees
Location
- Inogen, Inc.
- 301 Coromar Drive
- Goleta
- California
- 93117
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/24 00:00 |
| End of Day Share Price | 2022/06/24 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.